Q4 2024 Codexis Inc Earnings Call Transcript
Key Points
- Codexis Inc (CDXS) has successfully returned its pharma manufacturing business to a healthy growth trajectory.
- Significant progress has been made in reducing costs, strengthening the balance sheet, and defining a path to profitability.
- The ECO Synthesis platform is set to achieve commercial liftoff in 2025, with revenue-generating contracts expected to start in early Q2.
- The company has completed feasibility studies with multiple leading siRNA innovator companies, indicating strong commercial traction.
- Codexis Inc (CDXS) has established a new long-term agreement with Pfizer, providing future revenue opportunities.
- Revenue for the year ended December 31, 2024, was $59.3 million, down from $62 million the prior year, excluding PAXLOVID.
- Product gross margin decreased to 56% in 2024 from 63% in the prior year, excluding PAXLOVID, primarily due to product mix.
- R&D expenses increased in Q4 2024 compared to the previous year, driven by higher lab supplies and outside services costs.
- SG&A expenses rose to $13 million in Q4 2024, up from $12.2 million in Q4 2023, due to costs associated with executive departures.
- The net loss for the year ended December 31, 2024, was $65.3 million, compared to $84.4 million for the prior year, indicating ongoing financial challenges.
Welcome to the Codexis fourth quarter and full year 2024 Earnings conference call. (Operator Instructions) Please note that this event is being recorded.
And now, Iâll turn the call over to Carrie McKim, Director of Investor Relations. Please go ahead.
Thank you, operator. With me today are Dr. Stephen Dilly, Codexisâ President and Chief Executive Officer; Kevin Norrett, Chief Operating Officer; and Georgia Erbez, Chief Financial Officer.
During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2025 revenue, anticipated milestones, including product launches, pilot scale manufacturing, and paths to scale-up, technical milestones and public announcements related thereto, as well as our strategies and prospects for revenue growth, path to profitability, and successful execution of current and future programs and partnerships.
To the extent that statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
